Wall Street analyst estimates for Bluejay Diagnostics, Inc. (BJDX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 0.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-3520.00 | ||
| 2026-08-12 | $-1.12 | $-3520.00 | +100.0% |
| 2026-05-13 | $-1.95 | ||
| 2026-03-06 | $-2.37 | ||
| 2025-11-07 | $-4.04 | ||
| 2025-08-07 | $-5.64 | $-144.00 | +96.1% |
| 2025-05-13 | $-13.48 | $-1152.00 | +98.8% |
| 2025-03-31 | $-449.48 | $-832.00 | +46.0% |
Valuation Ratios
| Price / Book | 0.18 |
| EV / EBITDA | 1.21 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $249040 | 0 | 0 | 0 |
| Cost of Revenue | $142975 | $157039 | 0 | $200129 | 0 | 0 | 0 |
| Gross Profit | -$142975 | -$157039 | 0 | $48911 | 0 | 0 | 0 |
| Research & Development | $454610 | $527253 | $1.1M | $4.2M | $5.7M | $3.5M | $3.0M |
| Selling, General & Admin | $1.2M | $669138 | $2.1M | $5.2M | $4.6M | $3.7M | $3.9M |
| Operating Expenses | $1.5M | $1.0M | $3.2M | $9.4M | $10.3M | $7.2M | $7.0M |
| Operating Income | -$1.6M | -$1.2M | -$3.2M | -$9.3M | -$10.3M | -$7.2M | -$7.0M |
| EBITDA | -$1.5M | -$1.0M | -$3.0M | -$9.0M | -$9.2M | -$6.7M | -$6.7M |
| Interest Expense | 0 | $26997 | $367459 | 0 | 0 | $823028 | $839 |
| Pre-tax Income | -$819842 | -$1.2M | -$3.5M | -$9.3M | -$10.0M | -$7.7M | -$6.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$757716 | -$1.1M | -$3.7M | -$9.3M | -$10.0M | -$7.7M | -$6.8M |
| EPS | $-38.20 | $-56.76 | $-118.68 | $-292.88 | $-290.48 | $-456.76 | $-15.25 |
| EPS (Diluted) | $-38.20 | $-56.76 | $-118.68 | $-292.88 | $-290.48 | $-456.76 | $-15.25 |
| Shares Outstanding (Diluted) | $19835 | $19835 | $31425 | $31506 | $34266 | $45848 | $449043 |
Price
| Price | $0.81 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BCTXZ · ELAB · MLEC · MSPR · NKGN · TIVC · UPC
Explore sector: Healthcare · Medical - Devices
More sections of BJDX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks